| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Analysis of MafB deficient (MafB -/-) mice revealed that MafB is essential for podocyte differentiation and its foot process formation. However, the role of MafB in adult kidneys was not well known. Because MafB -/- mice die during the perinatal period, we used MafB heterozygote (MafB +/-) mice in this study.
We found that MafB +/- mice developed overt albuminuria at 50 week-old of age. By the electron microscopy analysis, we observed podocyte foot process effacement in MafB +/- mice. RT-PCR analysis revealed the Nephrin and Podocin glomerular expressions were decreased in MafB +/- mice compared to wild-type animals. We exploited transgenic mice expressing MafB in podocytes using Nephrin promoter (NPHS1 -MafB TG mice). We found that the NPHS1 MafB transgene successfully restored MafB mice to normal albuminuria at 50 week-old of age.
Conclusions: MafB is essential for the maintenance of podocytes. MafB could be a therapeutic target in chronic kidney disease.
|
